Mr. Swapan Kakumanu reports

NETRAMARK ENGAGES LODEROCK ADVISORS FOR STRATEGIC INVESTOR RELATIONS AND CAPITAL MARKETS COMMUNICATIONS SERVICES

Netramark Holdings Inc. has retained LodeRock Advisors Inc. for strategic investor relations and capital markets communications services, including working with Netramark senior management to plan, develop and execute a comprehensive IR program.

The program will consist of the development of a 12-month IR strategy including a marketing schedule, conducting investor targeting, analysis and outreach, working with investment dealers to organize non-deal road shows, and continuing capital markets counsel.

Under the terms of the agreement, Netramark will pay LodeRock a monthly fee of $11,000 for continuing strategic communication services. The services commence on Jan. 22, 2026, and will continue until terminated by either party with 60 days of written notice.

Neither LodeRock, nor any of its executives have an ownership interest, directly or indirectly, in Netramark or its securities, and Netramark will not issue any securities to LodeRock or its executives in consideration of the services. The company and LodeRock deal at arm's length and do not have any prior relationship.

LodeRock is a group of senior capital markets communications executives who develop and execute communications programs in order to help companies achieve their capital markets objectives and capture the full potential of their public listing.

About Netramark Holdings Inc.

Netramark is a company focused on being a leader in the development of generative artificial intelligence (gen AI)/machine learning (ML) solutions targeted at the pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows Netramark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent information that activates traditional AI/ML methods. The result is that Netramark can work with much smaller data sets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.

We seek Safe Harbor.